A pharmacokinetic-pharmacodynamic/toxicodynamic model framework for PARP inhibitor combination therapy with DNA-damaging chemotherapeutics

Cancer Chemother Pharmacol. 2026 Jan 20;96(1):11. doi: 10.1007/s00280-025-04862-w.

Li Chen ¹, Ronald W Bucher ¹, Derek W Bartlett ²

Affiliations

1 Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
2 Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. [email protected].

PMID: 41554954 DOI: 10.1007/s00280-025-04862-w

Keywords

Dose optimization; PARP inhibitor combination therapy; Resistance; Temozolomide chemotherapy; Time to progression; Virtual patients.

Products

Name
Email *

	Sorry, but the email address you supplied was invalid.